Zoladex versus Danazol in the Treatment of Pelvic Endometriosis: Effects on Plasma Lipid Risk Factors
article
OA: closed
CC0
⤵ 10 in-corpus citations
AI-generated summary
Danazol worsened CHD risk lipid profiles by increasing LDL and decreasing HDL, while Zoladex did not affect plasma lipids but increased HDL subfraction 3.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Plasma lipid risk markers for coronary heart disease (CHD) are influenced by sex steroid concentrations. Therapies that alter sex hormone levels have the potential to affect CHD risk. Zoladex had no effect on plasma lipids, but increased high density lipoprotein (HDL) subfraction 3, a lipoprotein of uncertain clinical significance. Danazol increased low density lipoprotein and decreased HDL concentrations to give a lipid profile associated with increased risk of CHD.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (10)
- Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue 2009
- Efeitos do sistema intra-uterino de Levonorgestrel sobre marcadores de risco cardiovascular de pacientes com endometriose: estudo comparativo com o análogo do GnRH 2009
- GnRH agonists and add‐back therapy: is there a perfect combination? 1998
- Goserelin 1996
- The impact of bone loss in women with endometriosis 1995
- Changing concepts of medical treatment of endometriosis 1993
- GnRH Agonists in the Treatment of Endometriosis 1993
- Report on a conference on developments in the treatment of benign gynecological disorders 1992
- Changes in body composition with danazol therapy 1991
- GnRH analogues in the treatment of endometriosis — rationale and efficacy 1991
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:09:15.954262+00:00
License: CC0
· commercial use OK